Search for: "BRISTOL-MYERS SQUIBB"
Results 761 - 780
of 866
Sorted by Relevance
|
Sort by Date
23 Jan 2018, 9:49 am
Bristol-Myers Squibb Co., et al. v. [read post]
17 Jul 2017, 9:41 am
Cir. 2012);see also Bristol-Myers Squibb Co. v. [read post]
19 Apr 2022, 8:00 am
In the Good, the Bad and Ugly: One Armed Man: I've been looking for you for 8 months. [read post]
15 May 2014, 11:40 am
I accept that, for the reasons explained by Jacob J in Bristol-Myers Squibb and Lord Hoffmann in Kirin-Amgen, courts should be cautious before relying upon prosecution history as an aid to construction. [read post]
6 Jun 2013, 5:00 am
Bristol-Myers Squibb Co., No. 12 Civ. 2238 (JPO), slip op. [read post]
20 Mar 2023, 7:52 am
Bristol-Myers Squibb Co., 2023 WL 2519857, SCAP-21-0000363, --- P.3d ---- (Hawai’i Mar. 15, 2023) The state sued two pharmaceutical companies for violating Hawai‘i’s Unfair or Deceptive Acts or Practices law (UDAP) by misleading the public about the safety and efficacy of their antiplatelet drug, Plavix. [read post]
2 Jun 2011, 12:46 pm
Squibb & Sons, Inc. v. [read post]
15 Aug 2021, 11:51 pm
Bristol-Myers Squibb The following case illustrates licence sought for Sprycel® which is used in cancer treatment On March 4, 2013 the Controller rejected BDR Pharmaceuticals’ (BDR) application for a compulsory license for the cancer drug Sprycel®. [read post]
8 Jul 2009, 7:04 am
(Spicy IP) India: Novartis patent rejection by the IPAB: Accessing the decision (Spicy IP) (IAM) India: Likely corruption in the Indian health care sector – Public interest litigation over government shutdown of vaccine production plants to enter contracts with private sector (IP Osgoode) Kenya: Manufacturers, public heath interests clash over anti-counterfeit law; AIDS patients to bring Constitutional challenge (Intellectual Property Watch) (Afro-IP) (Intellectual Property Watch) Spain:… [read post]
18 Feb 2020, 4:00 am
Pfizer Canada ULC, 2020 FC 1, at para. 57. [19] The claims are not limited to the “best mode,” often called the “preferred embodiment,” described in the specification or illustrated in the drawings: Bombardier Recreational Products Inc v Arctic Cat, Inc, 2018 FCA 172 at paragraph 54. [20] See Bristol-Myers Squibb Canada Co v Teva Canada Limited, 2016 FC 580 at paragraph 335. [21] That presumption was colourfully described as a ““judicial… [read post]
8 Jun 2023, 7:43 am
Examples of the latter include the Bristol-Myers-Squibb – Celgene merger in 2018, and the Merck-Wyeth merger of 2009. [read post]
26 Oct 2022, 3:17 am
(Nov. 24, 2021), https://ag.ny.gov/press-release/2021/attorney-general-james-secures-51-million-judgment-against-new-york-city-stem. [5] $834 Million Order Entered in Hawai‘i State Court against Bristol-Myers Squibb and Sanofi for Failing to Investigate and Disclose Ineffectiveness of Plavix®, Dept. of the Att’y Gen. [read post]
27 Jan 2017, 12:52 pm
The court also granted last Thursday in the much less colorful two-time relist Bristol-Myers Squibb Company v. [read post]
17 Jan 2007, 8:11 am
Other large companies that recently instituted or announced plans to adopt majority voting include Humana, Qwest Communications, AT&T, Bristol-Myers Squibb, Lexmark, Cummins, and McKesson, according to news reports. [read post]
5 Mar 2024, 11:47 am
PLAINTIFF COURT AND DATE OF COMPLAINT SELECTED DRUGS (FOR YEAR 2026) Bristol Myers Squibb D.N.J. (16 June 2023) Eliquis Novartis D.N.J. (1 Sept. 2023) Entresto J&J’s Janssen Pharms. [read post]
14 Dec 2017, 10:48 pm
The remaining manufacturers, including Bristol-Myers Squibb, ultimately settled for $3.4 billion, and Dow Corning resolved its claims in bankruptcy court. [read post]
23 Jul 2012, 7:33 am
In Bristol-Myers Squibb v. [read post]
8 Jun 2023, 7:43 am
Examples of the latter include the Bristol-Myers-Squibb – Celgene merger in 2018, and the Merck-Wyeth merger of 2009. [read post]
5 Jul 2015, 9:42 am
Bristol-Myers Squibb sought and obtained a commission in state court (New Jersey) cases for a Massachusetts’ subpoena for Garrido’s underlying data late in1997. [read post]
18 Sep 2023, 9:01 pm
Justice Sotomayor’s vote here was consistent with her dissent in a 2017 case involving suits filed by individuals from different states against Bristol-Myers Squibb (“BMS”) in California state court. [read post]
